What was the PAT in Cipla’s Q4 results?
- Answer Field
-
The PAT or Profit After tax in Cipla’s Q4 results was clocked at ₹939 Cr, an uptick of 79.1% YoY growth.
BAJAJ BROKING
Cipla Q4 FY 2023-24 results were released on 10 May 2024 with the Company generating growth in its metrics like Income rising 10% YoY, EBITDA up 13% YoY, and PAT at a record high. Trade Generics and Branded Prescription led Cipla’s winning growth trajectory.
Cipla’s Q4 results tell a growth story in the last quarter of FY24. With substantial progress across focused markets, the Company witnessed a quarter befitting of positive prospects with robust key financials. Here are 5 main financial highlights of Cipla’a Q4 results:
Explore: Cipla Share Price
As Cipla went through its last quarter of FY24, it witnessed growth across its businesses and geographies with resilience in its financial metrics and operational efficiencies. Here are some key aspects of the Company’s Q4 business achievements:
Metrics | Q4 FY24 | Q4 FY23 | YoY Growth |
Total Income from Operations | 6,163 | 5,602 | 10% |
EBITDA | 1,316 | 1,166 | 12.9% |
% of Income from Operations | 21.4% | 20.8% | 54 bps |
PAT | 939 | 524 | 79.1% |
Additional Read: Quarterly Results
Cipla’s Q4 results have laid the foundation for a great start to FY25. With the India business Chronic market share growth at more than 10% (4-year CAGR) for the Company, and other markets showing robust operations and financial strength, Cipla is about to go bigger and better in FY25. The Company is going ahead into the new financial year with a continuous growth momentum and is reserving a corpus to meet this goal. Across key therapies and segments, the Pharma major shows momentum that is structured on expansion, and this is in adherence with the Company’s plan for the next few quarters.
As a key contender in the Pharma sector, Cipla has made great breakthroughs in Q4 and FY24. The Company is making concentrated efforts to grow its main markets and open new ones. In FY24, as the Company’s Revenues crossed the threshold of ₹25,000 Cr, operating margins improved at a substantial rate and went over ₹6,000 Cr for the very first time, growing at a robust 14% on topline and 26% on profitability on a YoY basis. With prospects for increased profitability in the future months, Cipla is on track with its future aims.
Additional Read: ABB India Q4 Results
Established in 1935, Cipla is an old hand in the Pharma sector of India, making waves globally as it navigates its operations to sustain sound operations and financial goals. The aim of the Company has always been the sustenance of ‘agile growth’, especially on its home front, India. Since its inception, the Company has expanded its operations in South Africa, North America, and Emerging economies with its deepening portfolio of complex generics.
The Company’s strengths lie in the medical areas of urology, anti-retroviral, cardiology, respiratory, and CNS. Furthermore, the Company boasts a strong presence with its 47 manufacturing plants worldwide, with more than 50 dosage forms and over 1,500 products to date. Cipla has the added distinction of being ranked the 3rd largest Pharma company in India (IQVIA MAT March 2024), the largest pharmaceutical prescription market in South Africa (IQVIA March 2024), and the largest prescription drug provider in the US; Gx inhalation products (IQVIA MAT February 2024). By providing affordable healthcare for life-threatening conditions like HIV/AIDS in Africa, Cipla has made itself proud in the Pharma industry the world over.
Results for the Fourth Quarter and Full Year Ended March 31, 2024
Additional Read: venkys Q4 Results
Sources:
CIPLA Q4 Press Release on BSE
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Share Market Today | Gift Nifty Signals 100-Point Gap Down, Nifty to Consolidate
06 Sep, 2024 | 4 Min. read
KEC International Secures ₹1,423 Cr Transmission Line Order in Saudi Arabia
06 Sep, 2024 | 1 Min. read
Ashoka Buildcon’s Viva Highways Monetises Pune Land for ₹453 Crore
06 Sep, 2024 | 2 Min. read
Peak Partners To Sell 11% Stake in Indigo Paints via Block Deal
06 Sep, 2024 | 2 Min. read
US Initial Jobless Claims Drop to 227,000 in August.
06 Sep, 2024 | 1 Min. read
Commodities Market Today | WTI Crude Steady at $69.18, Gold Rises 0.8% to $2,546
06 Sep, 2024 | 1 Min. read
Gold Rate Today | Gold Rises 0.8% to $2,546, Silver Gains 2% to $29.14
06 Sep, 2024 | 2 Min. read
Vodafone Idea Share Price Falls 11% After Goldman Sachs Report
06 Sep, 2024 | 1 Min. read
Suzlon Energy Share Price Rises After Corporate Office Sale
06 Sep, 2024 | 1 Min. read
Why is the Stock Market Down Today? Key Factors Explained
06 Sep, 2024 | 1 Min. read
Sona BLW Precision Forgings Plans ₹2,400 Crore QIP at ₹675-700 per Share
05 Sep, 2024 | 1 Min. read
Commodities Market Today | Crude Oil Drops, Brent Hits Low; Gold and Silver Rise
05 Sep, 2024 | 1 Min. read
Analysis to Become a Pro Investor
28 Dec, 2023 | 4 Min. read
Women In Real Estate Investing (Investree)
28 Dec, 2023 | 5 Min. read
How To Check Prudent Corporate Advisory IPO Allotment Status
27 Dec, 2023 | 3 Min. read
How To Boost Credit Score? – Steps to Improve Creditworthiness
27 Dec, 2023 | 4 Min. read
Advantages and Disadvantages of Opening Multiple Demat Accounts
26 Dec, 2023 | 4 Min. read
7th CPC LTC: Leave Travel Concession Rules for Central Government Employees
26 Dec, 2023 | 4 Min. read
7th Pay Commission: House Building Advance (HBA) Interest Rate FY 2023-24
26 Dec, 2023 | 5 Min. read
The Future of Trading: Exploring Bajaj Broking’s Demat Features
26 Dec, 2023 | 6 Min. read
7th Central Pay Commission Cpc Fitment Table
23 Dec, 2023 | 7 Min. read
The PAT or Profit After tax in Cipla’s Q4 results was clocked at ₹939 Cr, an uptick of 79.1% YoY growth.
Cipla’s India business recorded a growth in its India business segment with growth recorded at 7% YoY, mainly on the back of Branded Prescription and Trade Generics.
The Cipla Q4 results portrayed growth in key segments of Cipla’s business segments with growth on the domestic and global front. The India business saw a growth of 7% YoY, while the North America business experienced a YoY growth of 11%. The South African business was not to be left out of the growth momentum and grew 26% YoY in local currency terms.
No Result Found
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading